• 5 min read
• Published on 19 August 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Pharma's Digital Prescription
For years, I’ve watched the pharmaceutical industry operate with a logic that would baffle an alien visitor. They invent a life-changing drug, price it at a level that requires a second mortgage, and then hand it over to a labyrinthine network of insurers and middlemen who decide who gets it. It’s a system that seems designed to frustrate everyone involved, most of all the poor soul who actually needs the medicine. But it seems the penny, or perhaps the billionth dollar, has finally dropped.
View the full Basket:Pharma's Digital Prescription
Let’s talk about Novo Nordisk. They make Ozempic, a drug that’s become so famous it’s practically a celebrity. Traditionally, getting your hands on it meant a battle with your insurance provider. But recently, Novo did something rather clever. They partnered with a digital platform called GoodRx to sell their drug directly to consumers at a more palatable price.
Now, don't mistake this for an act of corporate charity. This is a cold, calculated, and frankly brilliant business move. They’ve realised that the insurance companies, once their biggest customers, have become their biggest bottleneck. By going direct, they cut out the middleman, get their product straight into the hands of paying customers, and probably still make a handsome profit. It’s a win for them and a win for the patient. The only loser is the bureaucratic machine that’s been gumming up the works for decades.
View the full Basket:Pharma's Digital Prescription
You see, these digital health platforms have built something the pharmaceutical giants, for all their billions in research and development, never managed to build themselves. a direct, trusted relationship with the public. They are the digital chemists of the 21st century, handling prescriptions, offering advice, and, crucially, building a massive database of consumer behaviour.
For a company like Novo Nordisk or its rival Eli Lilly, this is gold dust. Partnering with these platforms gives them a direct channel to market, bypassing the gatekeepers. They can reach patients who were previously priced out, gather invaluable data on how their drugs are used, and even build a bit of brand loyalty by being seen as the company that finally made things affordable. It’s a fundamental shift from selling to systems to selling to people.
View the full Basket:Pharma's Digital Prescription
From an investor’s point of view, this is where things get interesting. This isn’t just a marketing gimmick. It’s a tectonic shift in the healthcare landscape. The obvious players are the big pharmaceutical companies who are smart enough to adapt. But I think the real opportunity might lie with the companies building the digital infrastructure that makes all this possible.
This whole trend points towards a new ecosystem where technology and medicine are inextricably linked. To me, this looks like a clear theme, a sort of Pharma's Digital Prescription for a potentially healthier portfolio. Of course, it’s not without its risks. The old guard won’t give up its lucrative position without a fight, and regulators will undoubtedly start sniffing around as these direct-to-consumer models become more common. Investing here requires a belief that this new model is not just a fad, but the future of how we access medicine. It’s a compelling argument, but not a guaranteed one.
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
View the full Basket:Pharma's Digital Prescription
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article